Work

Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

Year: 2018

Type: article

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-018-3731-4

Authors: on behalf of the ETCTN-6745 study team, Renu Singh, Shailly Mehrotra, Mathangi Gopalakrishnan, Ivana Gojo, Judith E. Karp, Jacqueline M. Greer, Alice Chen, Richard Piekarz, Brian F. Kiesel, Jogarao Gobburu, Michelle A. Rudek, Jan H. Beumer

Institutions: University of Maryland, Baltimore, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, National Cancer Institute, UPMC Hillman Cancer Center, UPMC Health System, University of Pittsburgh Medical Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, Cancer Institute, University of Pittsburgh, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: Phase I Clinical Trials of New Anti-Cancer Targeted Therapies, Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis, Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics, Institute for Clinical and Translational Research, NCI ETCTN Pittsburgh Cancer Consortium (PCC), The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies, Cancer Center Support Grant, Regional Oncology Research Center, Cancer Pharmacokinetics Research Specialist, G948547148

OpenAlex ID: W2901175244

FWCI: 0.276

Cites: 31

Cited by: 8

Related to: 10